Maxim Group Downgrades ImmunoCellular Therapeutics (IMUC) to Hold
Maxim Group downgraded ImmunoCellular Therapeutics (NYSE: IMUC) from Buy to Hold.Analyst Jason McCarthy highlighted:IMUC reported 3Q16 with a net loss ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)